Ameya Laboratories Ltd Stock Analysis

BSE: 532981 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Ameya Laboratories

M-Cap below 100cr DeciZen not available

Ameya Laboratories Price Chart

P/E Ratio (SA) :
Market Cap :
5.9 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Ameya Laboratories Ltd. a good quality company?

Data is not available for this company.

2. Is Ameya Laboratories Ltd. undervalued or overvalued?

No data found

3. Is Ameya Laboratories Ltd. a good buy now?

No data found

10 Year X-Ray of Ameya Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 0%14.2%27.2%32.7%37.2%31.6%15.5%13.3%11%7.8%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 026.362.790.3108150161204273268160
YoY Gr. Rt. %-NA138%44.1%19.4%39.5%6.9%27.2%33.4%-1.7%-
YoY Gr. Rt. %-NA180%178.6%112.8%31.3%-37.6%29.4%-25%-75.8%-
BVPS (₹)
Adj Net Profit
Cash Flow from Ops. 03.7-0.7-4.74.6-6.6-42.41328.5-10.1-
Debt/CF from Ops. 01.8-15.4-3.75.7-6.1-16.23.4-12.9-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA20%18.6%-1.7%
Adj EPS NA-28.1%-38.3%-75.8%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 011.833.654.658.843.216.513.8102.3-24.2
Op. Profit Mgn % 07.59.312.12122.420.917.716.914.86.9
Net Profit Mgn %
Debt to Equity
Working Cap Days 001111131261602712962212380
Cash Conv. Cycle 00112448891691821431690

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Ameya Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) -0.8 -
TTM Sales (₹ Cr.) 160 -
BVPS (₹.) 0 -
Reserves (₹ Cr.) -61 -
P/BV 0.00 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 0.23 / 0.25
All Time Low / High (₹) 0.17 / 28.57
Market Cap (₹ Cr.) 5.9
Equity (₹ Cr.) 24.5
Face Value (₹) 1
Industry PE 37

Management X-Ray of Ameya Laboratories :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *52.9937.4245.1245.1265.9666.1269.8969.1674.8473.79
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Ameya Laboratories

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Ameya Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Ameya Laboratories on 01-Jan-1970 05:30 is : 0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Ameya Laboratories stood at ₹ 5.87.
The latest PE ratio of Ameya Laboratories as of 01-Jan-1970 05:30 is 0.00.
The latest PB ratio of Ameya Laboratories as of 01-Jan-1970 05:30 is 0.00
The 52-week high of Ameya Laboratories is ₹ 0.25 and the 52-week low is ₹ 0.23.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Ameya Laboratories is ₹ 160.3 ( Cr.) .

About Ameya Laboratories Ltd

Anu's Laboratories is an ISO 9001:2000 certified company established in 1996, engaged in the manufacture of quality drug intermediates to meet the needs of international customers. The optimized process of 2, 4- Dichloro- 5 Fluoro Acetophenone has enabled the brand to establish itself as the flagship product of the organization. It is available to its wide customer base as a competitive product of the highest quality. Other high quality intermediates such as Chlorohexanone, 1, 3-Dibromo Propane are also available to its valued customers. The company is also producing Methyl- 4 (4-Chloro 1 oxo butyl), a Di-Methyl Acetate. Its state-of-the-art R&D facilities, located at Balanagar, Hyderabad, support the process of product development, contract research and customised synthesis programmes of the organization.

The company has entered into a job work agreement with Nitya Laboratories for manufacture of Sodium Methoxide or Sodium Methylate Solution and Powder and CIS (+) Hydroxide Lactum. Nitya Laboratories is one of the promoter group company involved in the manufacturing of fine chemicals and intermediates.

In 2010  Anu's Laboratories acquired Stilbene Chemicals Ltd.


  • Basic Intermediates
  • Advanced Intermediates
  • Fine Chemicals
  • Products in pipeline


  • The company received the state level Best SSI Entrepreneur Award for the year 2001-02 from the AP state government. 
  • The company was awarded the Market Penetration Leadership in the Indian Pharmaceutical Intermediates Market by M/s Frost & Sullivan for the year 2005.
  • Consistent and long-term relationship with customers.
  • Developed ‘A Cleaner Production Process’ by recovering by-products of commercial value from waste water.
  • Challenged the Chinese monopoly & attained leadership position in many of its products.
  • Developed and commercialized new intermediates; many more in pipeline.
  • ISO 9001 and Q9001-2000 Certifications.
  • Anu's R&D recognized by Department of Scientific and Industrial Research (DSIR), Government of India, New Delhi.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now